Castleman’s Disease - Clinical, Histological and Therapeutic Features

Marcu, Radu Dragos; Spinu, Arsenie Dan; Socea, Bogdan; Bodean, Maria Oana; Diaconu, Camelia Cristina; Vasilescu, Florina; Neagu, Tiberiu Paul; Bratu, Ovidiu Gabriel

Radu Dragos Marcu, Arsenie Dan Spinu, Bogdan Socea, Maria Oana Bodean, Camelia Cristina Diaconu, Florina Vasilescu, Tiberiu Paul Neagu, Ovidiu Gabriel Bratu

Castleman’s Disease - Clinical, Histological and Therapeutic Features

Abstract:

Castleman’s disease (CD) is a rare and benign lymphoproliferative pathology, characterized by lymphoid tissue hyperplasia, process that can occur at any site of the lymphoid chain. The purpose of this paper is to review the existing data regarding Castleman’s disease etiopathogenesis and treatment. Considering the extent of the lymphoid tissue involvement Castleman’s disease can be classified as unicentric (UCD) and multicentric (MCD). Another classification of this pathology is based on the histopathological features: hyaline vascular CD (90% of cases), plasma cell CD (less than 10%) and mixed cell type. Patients with UCD have good prognosis, the gold standard treatment being complete surgical excision. The multicentric type in contrast to UCD has a worse prognosis and associates the risk of evolving to lymphoma. Over the years different therapeutic strategies have been applied in the management of multicentric Castleman’s disease: glucocorticoids, chemotherapy, antiviral agents and monoclonal antibodies that target CD (cluster of differentiation) 20, interleukin -6 (IL-6) and IL-6 receptors. Castleman’s disease is a rare and complex pathology, whose etiopathogenesis is still incompletely elucidated. In the past few years the overall survival and progression free survival has significantly increased, due to different therapeutic options that have emerged, options that have constantly offered better and better results. Further investigation regarding the chemical interactions between different receptors and therapeutic molecules, understanding the mechanism of action and the potential benefits of each therapeutic agent may prove useful in clinical practice for treating CD.

Keywords:
Castleman’s disease; etiopathogeny; clinical features; treatment; outcome

Issue: 2018, Volume 69, Issue 4

Pages: 823-830

Publication date: 2018/5/15

https://doi.org/10.37358/RC.18.4.6208

Download Pdf Article

This article is published under the Creative Commons Attribution 4.0 International License

Citation Styles

Cite this article as:
MARCU, R.D., SPINU, A.D., SOCEA, B., BODEAN, M.O., DIACONU, C.C., VASILESCU, F., NEAGU, T.P., BRATU, O.G., Castleman’s Disease - Clinical, Histological and Therapeutic Features, Rev. Chim., 69(4), 2018, 823-830.

Vancouver
Marcu RD, Spinu AD, Socea B, Bodean MO, Diaconu CC, Vasilescu F, Neagu TP, Bratu OG. Castleman’s Disease - Clinical, Histological and Therapeutic Features. Rev. Chim.[internet]. 2018 Apr;69(4):823-830. Available from: https://doi.org/10.37358/RC.18.4.6208

APA 6th edition
Marcu, R.D., Spinu, A.D., Socea, B., Bodean, M.O., Diaconu, C.C., Vasilescu, F., Neagu, T.P. & Bratu, O.G. (2018). Castleman’s Disease - Clinical, Histological and Therapeutic Features. Revista de Chimie, 69(4), 823-830. https://doi.org/10.37358/RC.18.4.6208

Harvard
Marcu, R.D., Spinu, A.D., Socea, B., Bodean, M.O., Diaconu, C.C., Vasilescu, F., Neagu, T.P., Bratu, O.G. (2018). 'Castleman’s Disease - Clinical, Histological and Therapeutic Features', Revista de Chimie, 69(4), pp. 823-830. https://doi.org/10.37358/RC.18.4.6208

IEEE
R.D. Marcu, A.D. Spinu, B. Socea, M.O. Bodean, C.C. Diaconu, F. Vasilescu, T.P. Neagu, O.G. Bratu, "Castleman’s Disease - Clinical, Histological and Therapeutic Features". Revista de Chimie, vol. 69, no. 4, pp. 823-830, 2018. [online]. https://doi.org/10.37358/RC.18.4.6208

Text
Radu Dragos Marcu, Arsenie Dan Spinu, Bogdan Socea, Maria Oana Bodean, Camelia Cristina Diaconu, Florina Vasilescu, Tiberiu Paul Neagu, Ovidiu Gabriel Bratu,
Castleman’s Disease - Clinical, Histological and Therapeutic Features,
Revista de Chimie,
Volume 69, Issue 4,
2018,
Pages 823-830,
ISSN 2668-8212,
https://doi.org/10.37358/RC.18.4.6208.
(https://revistadechimie.ro/Articles.asp?ID=6208)
Keywords: Castleman’s disease; etiopathogeny; clinical features; treatment; outcome

RIS
TY - JOUR
T1 - Castleman’s Disease - Clinical, Histological and Therapeutic Features
A1 - Marcu, Radu Dragos
A2 - Spinu, Arsenie Dan
A3 - Socea, Bogdan
A4 - Bodean, Maria Oana
A5 - Diaconu, Camelia Cristina
A6 - Vasilescu, Florina
A7 - Neagu, Tiberiu Paul
A8 - Bratu, Ovidiu Gabriel
JF - Revista de Chimie
JO - Rev. Chim.
PB - Revista de Chimie SRL
SN - 2668-8212
Y1 - 2018
VL - 69
IS - 4
SP - 823
EP - 830
UR - https://doi.org/10.37358/RC.18.4.6208
KW - Castleman’s disease
KW - etiopathogeny
KW - clinical features
KW - treatment
KW - outcome
ER -

BibTex
@article{RevCh2018P823,
author = {Marcu Radu Dragos and Spinu Arsenie Dan and Socea Bogdan and Bodean Maria Oana and Diaconu Camelia Cristina and Vasilescu Florina and Neagu Tiberiu Paul and Bratu Ovidiu Gabriel},
title = {Castleman’s Disease - Clinical, Histological and Therapeutic Features},
journal = {Revista de Chimie},
volume = {69},
number = {4},
pages = {823-830},
year = {2018},
issn = {2668-8212},
doi = {https://doi.org/10.37358/RC.18.4.6208},
url = {https://revistadechimie.ro/Articles.asp?ID=6208}
}

<<<< back

PUBLISHING SECTION

Author Guidelines

* Paper Drafting

* Paper Template

* Ethical Statement

* Paper Submission

Ghidul Autorului (ro)

Open Access & Archiving Policy

Search Authors

LATEST NEWS
	NUMAR OMAGIAL PETRU PONI.. detalii
	Revista de Chimie - 70 de ani de aparitie neintrerupta.. detalii
	English-Romanian Dictionary for Mechanical Engineering (download pdf)